Corcept Therapeutics (CORT) investor relations material

Executive summary

• Q2 2026 revenue reached $256.1 million, a 32% year-over-year increase, driven by strong growth in endocrinology (Cushing's syndrome) and oncology, including the launch of Lifyorli.

• Lifyorli, approved for platinum-resistant ovarian cancer in March 2026, generated $47.6 million in its first quarter, with over 1,300 patients started on therapy.

• Net income for Q2 2026 was reported between $42.1 million and $43.0 million, up from $34.6–$35.1 million in Q2 2025.

• Record numbers of new prescriptions and prescribers in Cushing's syndrome business, with increasing physician awareness and patient screening.

• 2026 revenue guidance was raised to $1.1–$1.2 billion, reflecting confidence in continued business strength.

Financial highlights

• Q2 2026 product revenue: $256.1 million, up from $194.4 million in Q2 2025.

• Net income: $42.1–$43.0 million in Q2 2026, up from $34.6–$35.1 million in Q2 2025.

• Cash and investments as of June 30, 2026: $544.6–$545 million.

• Operating expenses rose to $214.8 million from $167.8 million year-over-year, mainly due to Lifyorli launch and Cushing's investments.

• Diluted EPS for Q2 2026: $0.36, up from $0.29 in Q2 2025.

Outlook and guidance

• 2026 revenue guidance raised to $1.1–$1.2 billion, reflecting strength in both endocrinology and oncology.

• Cushing's syndrome business expected to reach at least $2 billion in annual revenue by decade's end, with relacorilant potentially accelerating growth to $3–$5 billion.

• Lifyorli annual U.S. revenue projected to exceed $1 billion as adoption broadens.

• Anticipated FDA decision on relacorilant NDA by December 17, 2026; EMA approval for relacorilant in ovarian cancer also expected.

• Management expects to fund operations and R&D activities for the next 12 months and beyond without raising additional funds.